Dr. Ram Prakasha | Pediatric Physiotherapist | HealingwithRam | Pediatric Physiothrapy & Child Development Centre.

L1-79 and Autism Spectrum Disorder: An Evidence-Based Overview

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition associated with differences in social communication and interaction, together with restricted or repetitive patterns of behavior, interests, or activities. Autism is highly heterogeneous, meaning that symptoms and support needs can vary substantially from one person to another.

Because of this complexity, researchers have investigated a wide range of biological pathways that might contribute to autism-related symptoms. One investigational compound that attracted research interest is L1-79.

The interest in L1-79 and Autism Spectrum Disorder comes partly from its proposed effect on catecholamine pathways. L1-79 is described in the scientific literature as a racemic formulation of α-methylparatyrosine, a compound that inhibits tyrosine hydroxylase, an enzyme involved in catecholamine synthesis.

A 2019 PubMed-indexed study investigated L1-79 in a small prospective case series involving eight individuals with autism. The researchers reported improvements on several behavioral assessment measures in some participants, but they also emphasized that the findings needed confirmation in properly controlled double-blind studies.

Therefore, it is important to distinguish between research findings and an established autism treatment. L1-79 should not be presented as a proven cure or routinely recommended medication for autism.

What Is L1-79?

L1-79 is an investigational compound studied in relation to Autism Spectrum Disorder.

According to the 2019 PubMed-indexed publication, L1-79 is a racemic formulation of α-methylparatyrosine. The compound acts as a tyrosine hydroxylase inhibitor. Tyrosine hydroxylase is an important enzyme in the biochemical pathway responsible for producing catecholamine neurotransmitters.

Catecholamines include neurotransmitters such as:

Dopamine
Norepinephrine
Epinephrine

These neurotransmitters are involved in multiple neurological and physiological processes, including attention, arousal, motivation, movement, stress responses, and other functions.

The scientific interest in L1-79 therefore involves the possibility that modifying catecholaminergic activity could influence some behavioral characteristics associated with ASD.

However, a biological mechanism that appears theoretically relevant does not automatically mean that a medication will be clinically effective. A proposed mechanism must be supported by appropriately designed clinical trials.

Why Has L1-79 Been Studied in Autism?

Autism involves complex interactions among genetic, developmental, neurological, behavioral, and environmental factors. There is no single neurotransmitter or pathway that explains every autistic person’s characteristics.

Researchers have therefore investigated several neurotransmitter systems, including serotonergic, dopaminergic, glutamatergic, GABAergic, and catecholaminergic pathways.

The research surrounding L1-79 and Autism Spectrum Disorder focuses particularly on catecholaminergic inhibition.

The hypothesis is that altering catecholamine synthesis could potentially influence certain behavioral symptoms or functional characteristics in some individuals with ASD.

Importantly, this is a research hypothesis, not evidence that catecholamine inhibition is the underlying cause of autism.

The 2019 L1-79 Autism Study

One of the most frequently discussed publications involving L1-79 and autism was published in Clinical Therapeutics in 2019.

The PubMed record identifies the paper as:

“Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series.”

The study was published in volume 41, issue 10, pages 1972–1981, and has PubMed ID 31492568.

Study design

The investigators conducted a prospective case series.

The study included:

8 participants
6 males
2 females
Age range: 2.75 to 24 years
Treatment duration: 8 weeks
L1-79 doses ranging from 90 to 400 mg three times daily

Participants were evaluated using several clinical assessment tools, including:

Aberrant Behavior Checklist-Community (ABC-C)
Connor’s Parent Rating Scale (CPRS)
Clinical Global Impressions (CGI)
Autism Diagnostic Observation Schedule (ADOS)

These instruments were used to assess behavioral characteristics and changes during the study.

What Did the 2019 Study Find?

The researchers reported that ABC-C and CPRS scores improved between baseline and the end of the study for 7 of the 8 participants.

The publication also reported that some participants demonstrated improvements on clinical global impression measures.

For participants who completed ADOS assessments, the authors reported improvements in some individuals.

However, these findings need to be interpreted carefully.

The study had only eight participants and did not provide the level of evidence normally required to establish efficacy for a new treatment.

The authors themselves stated that the findings needed confirmation through double-blind studies.

This is an important point for healthcare professionals, parents, students, and anyone researching L1-79.

A positive finding in a small case series can generate a hypothesis, but it cannot establish that the treatment works for the broader autism population.

What Is the Mechanism of Action of L1-79?

The proposed mechanism of L1-79 involves tyrosine hydroxylase inhibition.

Tyrosine hydroxylase participates in the conversion of tyrosine into L-DOPA, an important step in catecholamine synthesis.

The simplified pathway can be described as:

Tyrosine → L-DOPA → Dopamine → Norepinephrine → Epinephrine

By inhibiting tyrosine hydroxylase, L1-79 is intended to influence catecholamine production.

Because dopamine and norepinephrine are involved in attention, arousal, motor regulation, motivation, and other neurological functions, researchers have investigated whether modifying this pathway might affect certain behavioral characteristics in ASD.

Nevertheless, autism is not simply a disorder of dopamine or norepinephrine. ASD is biologically heterogeneous, and neurotransmitter systems interact with multiple developmental and neural networks.

Therefore, the mechanism of L1-79 remains an area of research rather than a complete explanation of autism.

L1-79 and Dopamine

Dopamine is a neurotransmitter involved in several important neurological processes.

These include:

Motor control
Motivation
Reward processing
Attention
Learning
Executive functions

Because dopamine pathways are involved in several behaviors that may also be relevant to autism, researchers have investigated dopaminergic mechanisms in ASD.

L1-79 is different from a medication that simply supplies dopamine or directly stimulates dopamine receptors. Its proposed action occurs earlier in the catecholamine synthesis pathway through tyrosine hydroxylase inhibition.

This distinction is important when discussing L1-79 autism research.

L1-79 and Norepinephrine

Norepinephrine plays important roles in:

Attention
Arousal
Alertness
Stress responses
Cognitive processes

Changes in catecholaminergic signaling have been investigated in relation to several neurodevelopmental and psychiatric conditions.

The proposed effect of L1-79 on catecholamine synthesis is therefore relevant to research examining behavioral and cognitive symptoms.

However, more research is needed to determine whether these biological changes translate into meaningful functional improvements for people with ASD.

What Symptoms Were Studied?

The 2019 study did not treat autism as a single symptom.

Instead, researchers used standardized assessment tools to examine different behavioral and clinical characteristics.

The assessments included measures related to:

Irritability
Social withdrawal
Stereotypic behavior
Hyperactivity
Noncompliance
Inappropriate speech
Overall clinical impression
Autism-related symptoms

This is important because autism has multiple domains, and a medication might potentially affect one symptom domain without changing the overall developmental profile of an individual.

Is L1-79 an Approved Autism Medicine?

L1-79 should not be described as an established or approved treatment for the core symptoms of autism.

The 2019 publication was an early clinical investigation, and the authors explicitly stated that further double-blind studies were required.

Current regulatory information also distinguishes between treatments for autism’s core features and medications used for associated symptoms such as irritability.

For example, U.S. FDA materials state that there are no FDA-approved pharmacological treatments specifically targeting the core symptoms of ASD. Risperidone and aripiprazole have approvals related to irritability associated with autistic disorder, rather than the core features of ASD.

This distinction is essential.

L1-79 research does not mean L1-79 is a routine prescription for autism.

L1-79 Clinical Trial Evidence

A later clinical study provides additional information about L1-79 research.

ClinicalTrials.gov lists study NCT02947048, titled “Safety of L1-79 in Adolescent and Adult Males With Autism.”

The study was randomized and included placebo groups. The reported actual enrollment was 42 participants. The study investigated 100 mg and 200 mg L1-79 three times daily in different groups.

The reported results included several outcome measures, such as:

Clinical Global Impression
Vineland Adaptive Behavior Scale
ADOS-2
Aberrant Behavior Checklist-Community
Safety and adverse events

The ClinicalTrials.gov record also highlights important limitations, including the small sample size and the fact that the study was not powered to detect statistically significant changes in efficacy parameters.

This demonstrates why the development of a potential autism medication requires multiple stages of research.

Why Small Studies Cannot Prove a Treatment Works

When reading research about L1-79 and Autism Spectrum Disorder, it is important to understand study design.

A case series can provide valuable early information.

For example, researchers may observe:

Whether participants tolerate the compound
Whether symptoms appear to change
Which outcome measures may be useful
Whether a biological hypothesis deserves further investigation

But case series have major limitations.

They generally lack:

Large sample sizes
Strong control groups
Adequate randomization
Blinding
Sufficient statistical power

Therefore, positive results should be considered preliminary.

Randomized, placebo-controlled, double-blind trials generally provide stronger evidence about whether observed changes are attributable to the intervention rather than natural variation, expectations, concurrent treatment, or other factors.

L1-79 Safety Considerations

Safety is particularly important when discussing an investigational medication in children.

The 2019 case series reported three adverse events and described them as mild and resolving without changing therapy. The authors reported no medication adverse effects in their clinical global impression assessment.

However, a small study cannot establish the complete safety profile of a drug.

Rare adverse effects may not become apparent until a much larger number of people have been exposed.

For this reason, parents and caregivers should not attempt to obtain or administer L1-79 independently based on information from an online article, social media post, or research paper.

Any investigational treatment should be considered only under appropriate medical supervision and within applicable regulatory and research frameworks.

L1-79 vs Standard Autism Support

Autism management is generally individualized.

Depending on the person’s developmental profile and support needs, intervention may include:

Speech and language therapy
Occupational therapy
Physiotherapy
Behavioral interventions
Parent-mediated interventions
Educational support
Communication support
Social skills interventions
Management of co-occurring conditions

Medication, when used, is generally aimed at specific associated symptoms rather than treating autism as a whole.

For example, irritability, aggression, severe behavioral dysregulation, anxiety, sleep problems, ADHD symptoms, or seizures may require separate clinical assessment.

The treatment plan should therefore be based on the individual’s needs rather than on the diagnosis alone.

Can L1-79 Cure Autism?

There is currently no scientific basis for describing L1-79 as a cure for autism.

The 2019 study investigated whether L1-79 might improve certain clinical features associated with ASD. It did not demonstrate that L1-79 eliminates autism or changes the underlying developmental condition.

Autism is a lifelong neurodevelopmental condition for many people, although support needs and abilities can change substantially throughout development.

Research into medications should therefore focus on clearly defined clinical outcomes, such as improvements in specific symptoms, functioning, communication, participation, or quality of life.

What Can Parents Learn From the L1-79 Research?

Parents searching for information about L1-79 autism treatment should consider three major points.

1. L1-79 is an investigational compound

The available research does not establish L1-79 as a routine autism medication.

2. Early research showed signals that required further investigation

The 2019 case series reported improvements in several measures in some participants, but the sample was very small.

3. Treatment decisions should be individualized

Parents should discuss medication decisions with a qualified pediatrician, developmental pediatrician, child psychiatrist, or other appropriate medical professional.

What Does the Research Mean for Future Autism Treatment?

The development of new autism treatments is challenging because ASD is extremely heterogeneous.

Two children with the same diagnosis may have very different:

Communication abilities
Sensory profiles
Cognitive profiles
Behavioral characteristics
Sleep patterns
Motor abilities
Medical comorbidities
Learning needs

A medication that benefits one subgroup may not benefit another.

This is one reason researchers are increasingly interested in identifying biological markers and clinically meaningful subgroups.

L1-79 represents one example of a pharmacological hypothesis being investigated through clinical research.

Future research would need to determine:

Which individuals might respond
Which symptoms might improve
What dose is appropriate
How long treatment should continue
What adverse effects may occur
Whether improvements are clinically meaningful
Whether benefits remain after treatment
How L1-79 compares with placebo and existing interventions

Important Difference Between Research and Treatment

A PubMed publication is not automatically a treatment recommendation.

PubMed is a database containing biomedical literature. Finding a study about a compound does not mean that the compound is approved, proven, or appropriate for clinical use.

When reading research about L1-79 and Autism Spectrum Disorder, always look at:

Study design
Number of participants
Control group
Randomization
Blinding
Outcome measures
Statistical significance
Clinical significance
Adverse events
Replication by independent studies

This approach helps healthcare professionals and families distinguish promising research from established clinical evidence.

Frequently Asked Questions About L1-79 and Autism

What is L1-79?

L1-79 is an investigational compound described as a racemic formulation of α-methylparatyrosine. It inhibits tyrosine hydroxylase and has been investigated in relation to Autism Spectrum Disorder.

What is L1-79 used for?

L1-79 has been investigated experimentally in people with autism. It should not be presented as an established treatment for the core symptoms of ASD.

What was the 2019 L1-79 autism study?

The 2019 study was a prospective case series involving eight participants with ASD. Participants received L1-79 for eight weeks, and several behavioral and clinical measures were assessed.

Did L1-79 improve autism symptoms?

The 2019 study reported improvements in several assessment measures in some participants. However, because the study was very small and was not a definitive randomized controlled efficacy trial, the findings should be considered preliminary.

Is L1-79 FDA approved for autism?

L1-79 should not be considered an FDA-approved treatment for the core symptoms of ASD. FDA materials distinguish approved treatments for irritability associated with autistic disorder from treatments targeting the core features of ASD.

Does L1-79 cure autism?

No evidence establishes L1-79 as a cure for autism.

Can parents give L1-79 to a child?

Parents should not administer an investigational drug independently. Medication decisions for children should be made with an appropriately qualified healthcare professional.

Where can I find the original L1-79 research?

The 2019 study is indexed in PubMed under PMID 31492568.

Conclusion

Research into L1-79 and Autism Spectrum Disorder represents an interesting example of how researchers investigate biological pathways that may contribute to autism-related symptoms.

The 2019 PubMed-indexed case series reported improvements in several clinical measures among some participants treated with L1-79. However, the study included only eight participants, and the authors emphasized the need for confirmation through double-blind studies.

A later ClinicalTrials.gov record describes a randomized study involving 42 participants and reports multiple efficacy and safety outcomes, while also documenting limitations related to sample size and statistical power.

Therefore, L1-79 should currently be understood primarily in the context of autism research, rather than as a proven routine medication for ASD.

For families, the most important approach is individualized assessment and evidence-based support. For researchers and healthcare professionals, L1-79 may remain relevant as an example of a pharmacological pathway being investigated in ASD, but stronger and adequately powered clinical evidence is necessary before drawing firm conclusions about its clinical role.

Medical Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or a prescription. L1-79 is an investigational compound in the context discussed above. Parents and caregivers should not start, stop, or obtain medication for a child based solely on this article or a research paper. Discuss individual treatment decisions with a qualified healthcare professional.

References

Rothman J, Bartky EJ, Halas FP. Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clinical Therapeutics. 2019;41(10):1972–1981. PMID: 31492568.
ClinicalTrials.gov. Safety of L1-79 in Adolescent and Adult Males With Autism. NCT02947048.
U.S. Food and Drug Administration. Information regarding pharmacological treatment of irritability associated with autism and the lack of approved pharmacological treatments for core ASD symptoms.